Brainsway Ltd. (BWAY) Form 6-K — Oct 26, 2026
BrainsWay announced further expansion of U.S. insurance coverage for its Deep TMS treatment of OCD, with more than 118 million Americans now covered under policies providing access to the therapy. The company emphasized its position as the first to receive FDA clearance for non-invasive brain stimulation for OCD and the only TMS company with published randomized, placebo-controlled pivotal study data for the indication.
Key figures
- Indication
- OCD
- Covered lives
- 118000000
- Fda cleared indications
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.